
price close busi februari
medic devic heart valv therapi includ tissu
valv mechan valv repair product
biomed devic servic
tavr busi acceler still plenti
upsid view increas target buy
bottom line keep buy ew top larg cap pick analysi
suggest stock trade least year-end base sole
fundament current evid busi let alon potenti upsid
trend busi part past year what
ew trade large-cap regress analysi suggest think
possibl next month ew close eye-open result
headlin domest tavr busi acceler y/i growth notabl
firm forward outlook tavr market strengthen base therapi
adopt trend see time span decemb analyst day
present tavr trend clearli key compon drove increas
revenu guidanc inde revenu across three busi unit expect
come high end previous state rang tax save bp
new us tax bill contribut cent cent upwardly-revis pro
forma ep margin expans driven primarili
higher tavr revenu estim contribut rest speak tavr leverag
om line om leverag model evalu potenti ep upsid stem
nomin dollar growth y/i ww tavr suggest firm ep could come
high without contempl upsid current estim
favor ew laser focus attract larg under-penetrated structur
heart market address larg patient popul need better therapi
also favor firm product pipelin approach regulatory/tri strategi tavr
 highlight updat beyond near-term continu
take favor view businesss long-term potenti back sheer
size tavr coupl posit growth trend earn leverag
mitral/tricuspid opportun fit ew core compet structur heart-
us tavr busi ew domest tavr busi deliv growth
quarter exact acceler ahead growth benchmark
stronger end-of-quart sale vs histor trend well robust growth
lower-volum center contribut market growth ew grow in-line
overal us market specif lower volum center side
develop build referr base continu augment growth
next major catalyst tavr growth us remain low-risk approv track
late think posit tavr trend coupl manag
bullish outlook thv sale paint improv growth pictur interim
period vs previous assum also see underappreci potenti
catalyst forthcom launch ultra aka sapien us late
continu pg
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
us tavr busi continu recent physician check highlight ultra
platform eas deliveri superior current platform key posit
physician focu current industri focu optim tavr
structur heart pipelin updat firm global tavr busi ew expect
receiv ce mark ultra quarter centera ce mark expect
end current month regard centera ew plan posit valv
premium self-expand platform europ maintain asp
averag market rate firm expect commenc us pivot trial
new news believ view posit street
side portfolio manag reiter long-term
outlook market view combin market opportun
europ ew cardioband mitral sale manag
anticip total cardioband mitral sale full year sale
ramp throughout year ew addit announc recent receipt ce
mark harpoon firm project control launch
europ regard clinic progress enrol firm activ cardioband
mitral trial us continu progress pascal enrol clasp
ce mark trial pace complet subsequ ce mark
expect firm expect initi us trial pascal within
current calendar year specif replac side ew mitral
portfolio manag note continu progress cardiaq sapien
platform system leverag fulli percutan ts
approach continu believ ew best posit win burgeon
transcathet mitral/tricuspid field via expans comprehens product
pipelin portfolio laser focu structur heart larg global presenc
 salesforc realm
posit guidanc updat base strength seen sale trend
well posit fx outlook manag updat full-year
guidanc expect total sale come higher end previous
state rang incorpor ew updat outlook
firm expect come high end previous commun
guidanc rang three busi unit total tavr thvt sale
rang total surgic heart revenu
rang total critic sale
full year adjust ep expect rang
prior rang increas incorpor
project benefit lower tax rate manag guid sale
rang adjust ep
buy unchang target price februari
biomed devic servic
figur edward result vs cg estim consensu project
deriv price target appli price-to-earnings
pro forma ep
buy unchang target price februari
biomed devic servic
actual except resultsprior yeary/i growthcg estim varianc varianceconsensustranscathet heart valv heart guidancep/e/g valuat financi metric use current median large-cap medic devic price-to-earnings multipl ex outlier med-tech comp group ep compound-annual-growth-rate forward impli ew ep pro forma compound-annual-growth-rate forward p/e/g multipl price-to-earnings multipl forma mo figur tavi
buy unchang target price februari
biomed devic servic
symptomat patient year year year american age aortic age sever sever symptomat etiolog s/ ssa primari etiolog pe patient yr severe/symptomat ssa pe patient yr yr severe/symptomat ssa pe patient consid high risk surgeri consid intermedi risk surgeri consid risk surgeri consid high risk surgeri consid intermedi risk surgeri consid risk surgeri tavr market opportun tavr market opportun aortic stenosi elderli diseas preval number candid transcathet aortic valv replac meta-analysi model studi canaccord genuiti estim -conserv assum preval old age euroheart survey primari reason age lv canccord genuiti primari research ew compani report investor day assum ou market europe/japan us figur tavi ww market share
buy unchang target price februari
biomed devic servic
edward lifesci averag implant center total asp ew ww tavi revenu ex growth averag total asp ww tavi revenu growth averag total asp ww tavi revenu growth player ww tavi revenu ww implant patient popul high player tavi ww revenu market lifesci implant averag implant total asp ew us revenu averag total asp total us revenu averag total asp us revenu player us revenu us implant address patient penetr us tavr market figur tavi eu/row market share
buy unchang target price februari
biomed devic servic
detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact inform appear front page report
buy unchang target price februari
biomed devic servic
million except per share revenu incl stock total revenu gross oper expens incom pre-tax incom tax interest exp eitf add-back net incom share ep forma ex ia margin analysi gross margin pro sale sale y/i revenu growth growth growth incom pro forma incom forma ex-one-tim ia figur revenu model
buy unchang target price februari
biomed devic servic
heart valv aortic/mitr replacement/repairaort tavi sapien product royalti total tavi mitral/trucuspid tmvr/re usous- total tmvr/re revenue- total transcathet surgic heart valv therapytissu repair surgic heart valv cardiac perfusion/cannula cardiac surgeri total surgic hv cs critic hemodynam pressur critic vascular catheter-bas angioscopi vascular total critic vascular total revenu pro forma total revenu figur revenu model part
buy unchang target price februari
biomed devic servic
